LGALS9 and neoplasm: In stark contrast to those of normal mice, in the background of immunodeficiency, the tumor growth rate and survival time of GL-261nSMase2−/−, Rab27a−/−, and LGALS9−/− tumor-bearing mice were not significantly different from those of GL-261WT tumor-bearing mice.